Codexis Down on 3Q Rev Decline, CEO Change

Dow Jones

Nov 07

By Josh Beckerman

Shares for Codexis were falling after the biotechnology company reported third-quarter earnings and sales that disappointed Wall Street.

The stock fell 21% to $1.60 in after-hours trading Thursday. Ahead of the market close, shares were already down 57% year to date.

Codexis reported a loss of $19.6 million, or 22 cents a share for the quarter ended Sept. 30, compared with a loss of $20.6 million, or 29 cents a share. Analysts polled by FactSet expected a more shallow loss of 15 cents a share.

Revenue declined to $8.6 million in the third quarter from $12.8 million in the year-ago quarter due to variability in customers' manufacturing schedules and clinical trial progression. Analysts expected $18.5 million.

Codexis said it has appointed Alison Moore as its next chief executive, succeeding Stephen Dilly, who will remain chairman. As it enacted leadership changes, the company cut 46 jobs, or about 24% of its workforce in November.

The company also said it signed a $37.8 million supply assurance agreement with Merck that it says will provide "a substantial non-dilutive cash infusion."

"We feel it is the right time to complete our transition to an innovative manufacturing solutions provider in the field of oligonucleotide manufacturing," Dilly said.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

November 06, 2025 17:48 ET (22:48 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581041140"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581041140\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581041140?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 06:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581041140","market":"sg","top_or_hot":-1,"title":"Codexis Down on 3Q Rev Decline, CEO Change","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares for <a href=\"https://laohu8.com/S/CDXS\">Codexis</a> were falling after the biotechnology company reported third-quarter earnings and sales that disappointed Wall Street. \n</p>\n<p>\n  The stock fell 21% to $1.60 in after-hours trading Thursday. Ahead of the market close, shares were already down 57% year to date. \n</p>\n<p>\n  Codexis reported a loss of $19.6 million, or 22 cents a share for the quarter ended Sept. 30, compared with a loss of $20.6 million, or 29 cents a share. Analysts polled by FactSet expected a more shallow loss of 15 cents a share. \n</p>\n<p>\n  Revenue declined to $8.6 million in the third quarter from $12.8 million in the year-ago quarter due to variability in customers' manufacturing schedules and clinical trial progression. Analysts expected $18.5 million. \n</p>\n<p>\n  Codexis said it has appointed Alison Moore as its next chief executive, succeeding Stephen Dilly, who will remain chairman. As it enacted leadership changes, the company cut 46 jobs, or about 24% of its workforce in November. \n</p>\n<p>\n  The company also said it signed a $37.8 million supply assurance agreement with Merck that it says will provide \"a substantial non-dilutive cash infusion.\" \n</p>\n<p>\n  \"We feel it is the right time to complete our transition to an innovative manufacturing solutions provider in the field of oligonucleotide manufacturing,\" Dilly said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2025 17:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Codexis Down on 3Q Rev Decline, CEO Change</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCodexis Down on 3Q Rev Decline, CEO Change\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-07 06:48</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares for <a href=\"https://laohu8.com/S/CDXS\">Codexis</a> were falling after the biotechnology company reported third-quarter earnings and sales that disappointed Wall Street. \n</p>\n<p>\n  The stock fell 21% to $1.60 in after-hours trading Thursday. Ahead of the market close, shares were already down 57% year to date. \n</p>\n<p>\n  Codexis reported a loss of $19.6 million, or 22 cents a share for the quarter ended Sept. 30, compared with a loss of $20.6 million, or 29 cents a share. Analysts polled by FactSet expected a more shallow loss of 15 cents a share. \n</p>\n<p>\n  Revenue declined to $8.6 million in the third quarter from $12.8 million in the year-ago quarter due to variability in customers' manufacturing schedules and clinical trial progression. Analysts expected $18.5 million. \n</p>\n<p>\n  Codexis said it has appointed Alison Moore as its next chief executive, succeeding Stephen Dilly, who will remain chairman. As it enacted leadership changes, the company cut 46 jobs, or about 24% of its workforce in November. \n</p>\n<p>\n  The company also said it signed a $37.8 million supply assurance agreement with Merck that it says will provide \"a substantial non-dilutive cash infusion.\" \n</p>\n<p>\n  \"We feel it is the right time to complete our transition to an innovative manufacturing solutions provider in the field of oligonucleotide manufacturing,\" Dilly said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 06, 2025 17:48 ET (22:48 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2581041140","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581041140","pubTimestamp":1762469280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares for Codexis were falling after the biotechnology company reported third-quarter earnings and sales that disappointed Wall Street.The stock fell 21% to $1.60 in after-hours trading Thursday. Ahead of the market close, shares were already down 57% year to date.Codexis reported a loss of $19.6 million, or 22 cents a share for the quarter ended Sept. 30, compared with a loss of $20.6 million, or 29 cents a share. Analysts polled by FactSet expected a more shallow loss of 15 cents a share.Revenue declined to $8.6 million in the third quarter from $12.8 million in the year-ago quarter due to variability in customers' manufacturing schedules and clinical trial progression. Analysts expected $18.5 million.Codexis said it has appointed Alison Moore as its next chief executive, succeeding Stephen Dilly, who will remain chairman. As it enacted leadership changes, the company cut 46 jobs, or about 24% of its workforce in November.The company also said it signed a $37.8 million supply assura","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","CDXS":"Codexis"},"translate_title":"Codexis因第三季度营业额下降、首席执行官变动而下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CDXS":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares for Codexis were falling after the biotechnology company reported third-quarter earnings and sales that disappointed Wall Street. \n\n\n  The stock fell 21% to $1.60 in after-hours trading Thursday. Ahead of the market close, shares were already down 57% year to date. \n\n\n  Codexis reported a loss of $19.6 million, or 22 cents a share for the quarter ended Sept. 30, compared with a loss of $20.6 million, or 29 cents a share. Analysts polled by FactSet expected a more shallow loss of 15 cents a share. \n\n\n  Revenue declined to $8.6 million in the third quarter from $12.8 million in the year-ago quarter due to variability in customers' manufacturing schedules and clinical trial progression. Analysts expected $18.5 million. \n\n\n  Codexis said it has appointed Alison Moore as its next chief executive, succeeding Stephen Dilly, who will remain chairman. As it enacted leadership changes, the company cut 46 jobs, or about 24% of its workforce in November. \n\n\n  The company also said it signed a $37.8 million supply assurance agreement with Merck that it says will provide \"a substantial non-dilutive cash infusion.\" \n\n\n  \"We feel it is the right time to complete our transition to an innovative manufacturing solutions provider in the field of oligonucleotide manufacturing,\" Dilly said. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 17:48 ET (22:48 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}